A Willis Consulting

About Us

A Willis Consulting has been established since January 2012 and is a bespoke Regulatory consulting and training company, with a wealth of technical and practical experience in regulatory affairs, licensing and strategic development.  We can provide your company with advice, guidance and resources throughout your product lifecycles.

Our team of consultants each have at least 10 years’ experience and provide collective and individual expertise that enables you to meet your technical and business goals.  We pride ourselves on the ability to deliver consistently successful outcomes for our clients.

We provide a flexible and approachable service that can be tailored to the needs of the individual client and project.

Client projects throughout the world are managed from our UK and Portuguese bases.  We can manage any scale and duration of your project and A Willis Consulting are committed to delivering a successful outcome that exceeds your expectations.

Andrew Willis

Andrew Willis is a regulatory expert with 32 years of experience in pharmaceutical development.  Experience at multiple levels within pharmaceutical companies and most recently as Vice President for Regulatory Affairs, gaining significant experience in co-ordinating, planning and running global development projects.

His experience is wide ranging, and will facilitate your understanding of fast, effective development of medicinal products, through early stages, through registration and continued Life Cycle Management.

Andrew has a wealth of experience which he will share from his multiple roles he has been involved with in the pharmaceutical industry, including:

• Support and strategic advice for immunotherapies and ATMP stem cell medicines

• Interim Strategic advice to major pharmaceutical company for roll-out and compliance strategies for Russia / CIS, MENA, ASEAN, LATAM, South Africa and Switzerland,including ensuring appropriate staff development and strategies which ensure protection of intellectual property whilst maintain patient focus.

• Orphan drug registrations of vaccine products and synthetic molecules

• NCE approved in US and Europe for urology product (Simultaneous NDA and EU Centralised submission)

• Support for NBE during clinical phases and CMC support for a Biosimilar